hybrid FC fusion proteins (Genexine)

N/A

Report date: 2025/03/20 20:00:06

Base Information

Drug Namehybrid FC fusion proteins (Genexine)
Drug Alias Namehybrid Fc fusion protein therapy (Genexine)
ClassificationBiologics > Protein drugs > Recombinant protein > Fusion proteinBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody fragment
Mechanisms of ActionCoagulation modulators
TargetsUpdating
Therapy Area/IndicationsGrowth hormone deficiencyDiabetes MellitusNeutropenia +[5] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritorySouth Korea
CombinationsNo
Global Highest StatusPending (Phase 1 Clinical)
Highest Status in ChinaN/A
Originator CompaniesGannex Pharma Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesGannex Pharma Co Ltd
Active IndicationsN/A
Inactive IndicationsGrowth hormone deficiencyDiabetes MellitusNeutropenia +[5] 

Other Information

ATC CodeN/A
Related LinksN/A